phase II studi fluorouracil recombin interferon advanc colorect carcinoma phase II clinic trial fluorouracil recombin interferon rifn untreat patient measur metastat colorect cancer week continu intraven infus consecut day intraven bolu administr week day rifn roferon hoffman-laroch nutley NJ time week patient respons week patient studi assess toxic assess respons fifteen patient partial respons patient clinic complet respons overal respons rate confid interv CI median durat respons month rang month seventi percent patient studi aliv median follow-up durat month twenty-f percent patient toxic grade toxic drug-rel death presenc sepsi treatment-rel seizur experi schedul respons rate toxic current trial schedul rifn folin acid leucovorin single-ag role treatment advanc colorect carcinoma 